Remove Clinical Trials Remove Food Remove Patients
article thumbnail

CBD Topical Medicine: What Does the Science Say?

Project CBD

Consider it a testament to the ubiquity and flexibility of the endocannabinoid system: we can inhale medicinal cannabinoids via combustion or vaporization; ingest them via food or drink; and absorb them directly through the skin, the bodys largest organ. New clinical trials are urgently needed, they repeat in a familiar refrain.

article thumbnail

Medical Cannabis and Anxiety: Natural Treatment Options

Miss Marijuana

Clinical trials have been looking into both THC and CBD and their individual roles in treating anxiety. So, be patient! The key is to start slow, be patient, and keep track of how your body responds. Also, staying hydrated and eating nutrient-dense foods can have a big impact on how you feel throughout the day.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves Ketamine Nasal Spray as First and Only Standalone Therapy for Treatment-Resistant Depression

Veriheal

In January, the US Food and Drug Administration (FDA) approved the Johnson & Johnson brand nasal spray, Spravato®, as the world’s first and only monotherapy for addressing treatment-resistant cases of major depressive disorder (MDD).

article thumbnail

MDMA Failed to Receive FDA Approval: What Happens Next?

Veriheal

Drug company Lykos Therapeutics, which had filed the new drug application for MDMA therapy , was informed by the US Food and Drug Administration (FDA) that the data submitted was insufficient to receive approval, requesting that the company conduct an additional Phase 3 trial to further test the safety and efficacy of the drug.

article thumbnail

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

Cannabis Law Report

(“IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.

article thumbnail

Knowde Group Inc.™ Enters Into a Strategic Partnership with LMC Manna Research to Drive Quality and Collaboration in the Conduct of Cannabis and Psychedelic Clinical Trials.

Cannabis Law Report

There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Extensive early phase experience with appropriate safety oversight and early phase clinic.

article thumbnail

Japanese Officials Approve Epidiolex For Clinical Trials

Cannabis Law Report

The trials, to be tightly controlled in a hospital environment, are exempted from Japan’s Cannabis Control Act, which bans cannabis compounds generally. Food and Drug Administration last year. In Japan, there are approximately 3,000 patients who suffer from Dravet Syndrome, and some 4,300 afflicted with Lennox-Gastaut.